Premium
Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith–wiedemann syndrome
Author(s) -
Yamamoto Shohei,
Toyama Daisuke,
Yatsuki Hitomi,
Higashimoto Ken,
Soejima Hidenobu,
Isoyama Keiichi
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22650
Subject(s) - medicine , beckwith–wiedemann syndrome , chemotherapy , acute leukemia , toxicity , leukemia , incidence (geometry) , oncology , pediatrics , genetics , gene , gene expression , physics , optics , dna methylation , biology
Abstract Beckwith–Wiedemann syndrome (BWS) is characterized by an accumulation of multiple congenital anomalies. Although patients with BWS are known to have a higher incidence of embryonal tumors, there has been no reports associated with acute leukemia. This report describes the case of a patient with BWS who developed Acute Megakaryocytic Leukemia (AMKL,FAB;M7). Because most patients with BWS present gigantism, the therapy‐related toxicity of chemotherapy can be a very serious problem. This patient exhibited no therapy‐related toxicity after chemotherapy, suggesting that acute leukemia with BWS may not require a reduction in dosage. Pediatr Blood Cancer. 2010;55:733–735. © 2010 Wiley‐Liss, Inc.